Last updated: March 27, 2026
What is the drug identified by NDC 49483-0682?
The National Drug Code (NDC) 49483-0682 corresponds to Repatha (evolocumab), a monoclonal antibody used to lower LDL cholesterol. Approved by the FDA in August 2015, Repatha is primarily indicated for heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, and clinical atherosclerotic cardiovascular disease.
Market Dynamics for Evolocumab
Market Size and Penetration
The global hyperlipidemia market was valued at approximately USD 9 billion in 2022, with PCSK9 inhibitors like Repatha capturing a significant share. In the U.S., roughly 15 million adults have high LDL cholesterol, but only an estimated 2-3 million are prescribed PCSK9 inhibitors.
Competitive Landscape
Repatha's main competitor is Praluent (alirocumab) by Sanofi/Regeneron, launched in 2015. The two drugs have comparable efficacy, with Repatha exhibiting marginally higher LDL reduction (up to 60%) at higher doses. Recent market innovations include biosimilar efforts and expanding indications.
Market Trends
- Expansion into indications for primary prevention shows promise.
- Increased utilization is tied to updated lipid guidelines emphasizing aggressive LDL reduction.
- Prices and payer restrictions limit access, impacting market penetration.
Pricing Analysis
Current Pricing Structure
- Repatha's wholesale acquisition costs (WAC): approximately USD 5,850 per year per patient.
- Average negotiated net prices are estimated between USD 4,200 and USD 4,800 annually.
- The list price has remained relatively stable since launch, but discounts and rebates reduce the net expense for payers.
Price Comparison
| Drug |
WAC per Year |
Estimated Net Price |
Launch Date |
| Repatha (evolocumab) |
USD 5,850 |
USD 4,200–4,800 |
August 2015 |
| Praluent (alirocumab) |
USD 4,500 |
USD 2,200–2,800 |
July 2015 |
Reimbursement and Payer Dynamics
Insurance coverage favors drugs with demonstrated cost-effectiveness. Repatha faces prior authorization hurdles and step therapy requirements, which impact market share.
Price Projections
Short-Term (Next 1-2 Years)
- Stable list prices amid ongoing negotiations.
- Payer pressure may continue to limit net prices; discounts may range from 30% to 40%.
- New indications and combination therapies could influence demand.
Medium to Long-Term (3-5 Years)
- Potential price erosion driven by biosimilar entry.
- Introduction of alternative therapies, such as gene editing and RNA-based approaches, may lower prices.
- Payer focus on value-based contracting could push net prices lower, possibly below USD 3,500 per year.
Impact of Biosimilars
- Biosimilar development for PCSK9 inhibitors is underway; biosimilars for evolocumab are expected within 3–5 years.
- Biosimilars could reduce prices by 20–40%, depending on market acceptance and regulatory pathways.
Regulatory and Market Outlook
- FDA approval for expanded uses may increase usage.
- Cost-effectiveness assessments by agencies like NICE influence pricing.
- Patent expiry expected around 2028-2030, which will accelerate biosimilar competition and price reductions.
Risks to Price Stability
- Enhanced payer utilization management strategies.
- Introduction of lower-cost alternatives.
- Potential for price caps or legislation regulating drug prices.
Summary
Repatha remains a leading PCSK9 inhibitor with a stable but high list price. Market penetration is limited by payer restrictions and competition. Price erosion is anticipated as biosimilar options emerge and healthcare policies increasingly emphasize cost-effectiveness.
Key Takeaways
- Repatha's annual net price is estimated between USD 4,200–4,800; long-term reductions are probable.
- Biosimilar competition could reduce prices by 20–40% within 3–5 years.
- Market growth hinges on expanded indications, guideline endorsements, and payer acceptance.
- The patent expiry window (2028-2030) marks a critical period for pricing disruption.
- Cost containment measures, such as value-based agreements, remain a prominent factor influencing net prices.
FAQs
1. What factors most influence Repatha’s price?
Repatha’s price is driven by manufacturing costs, payer negotiations, competition, and regulatory policies affecting biosimilar entry.
2. How does payer coverage impact Repatha’s market price?
Payer restrictions, prior authorization, and reimbursement caps limit market access, often leading to negotiated net prices lower than the list.
3. Will biosimilars significantly reduce Repatha’s price?
Yes. Biosimilars could cut prices by up to 40%, primarily through increased competition and market share shifts.
4. What is the expected timeline for biosimilar entry?
Biosimilar versions are anticipated within 3-5 years, potentially around 2026-2028, depending on regulatory approvals and market dynamics.
5. How might regulatory changes influence future pricing?
Regulations encouraging price transparency, caps, and value-based pricing could lower overall drug prices in the coming years.
References
[1] FDA. (2022). FDA Approvals for PCSK9 inhibitors. U.S. Food and Drug Administration. Retrieved from https://www.fda.gov
[2] IQVIA. (2022). The Digital 100 Top Prescribed Drugs Report. IQVIA Institute for Human Data Science.
[3] Pharmerit. (2021). Cost-effectiveness of PCSK9 inhibitors. Journal of Medical Economics, 24(2), 123-132.
[4] NICE. (2022). Repatha appraisal and guideline updates. National Institute for Health and Care Excellence.
